This page is part of the Genetic Reporting Implementation Guide (v0.1.0: STU 1 Ballot 1) based on FHIR v3.3.0. The current version which supercedes this version is 2.0.0. For a full list of available versions, see the Directory of published versions

0 Table of Contents

..0 Table of Contents
...1 CG IG Home Page
....1.1 Genomics Primer
....1.2 General Genomic Reporting
....1.3 Sequenced Variants
....1.4 Cytogenomic Reporting
....1.5 Pharmacogenomic Reporting
....1.6 Somatic Genomic Reporting
....1.7 Genomic Profiling for Transplantation
....1.8 Conversion from STU3
....1.9 Appendix A: Relation to v2 reporting
....1.10 Appendix B: Clinical Genomic Apps
....1.11 Appendix C: Querying Genomics Information
...2 Artifact List
....2.1 Base observation common properties
....2.2 CG Diagnostic Report
....2.3 CG Specimen
....2.4 Recomended Followup
....2.5 Order for Genetics Test
....2.6 Genetic Panel
....2.7 Genetic analysis overall interpretation
....2.8 Deletion-duplication overall interpretation
....2.9 Chromosome analysis overall interpretation
....2.10 Descriptive Genetic Finding
....2.11 Computable Genetic Finding
....2.12 Haplotype
....2.13 Genotype
....2.14 Cytogenic Notation
....2.15 Complex Variant
....2.16 Described Variant (Discrete or Structural)
....2.17 Definitional Sequence
....2.18 Sequence Configuration
....2.19 Genetic Impact
....2.20 Inheritable Disease Pathology
....2.21 Chromosome analysis G-banding panel
....2.22 Chromosome Analysis FISH panel
....2.23 Chromosome copy number change panel
....2.24 Device Micro-array Platform
....2.25 DeviceComponent Fish Probe
....2.26 Genetic Medication Impact
....2.27 Genotype medication metabolism impact
....2.28 Genotype medication efficacy impact
....2.29 High Risk Allele
....2.30 Medication Adjustment Proposal
....2.31 Current Medication
....2.32 Somatic Impact
....2.33 Somatic Diagnostic Impact
....2.34 Somatic Prognostic Impact
....2.35 Somatic Predictive Impact
....2.36 Related Artifact
....2.37 Recommended action
....2.38 Supporting Information
....2.39 Focus
....2.40 Recommended action
....2.41 Unsolicited?
....2.42 Manufacturer
....2.43 CG Test
....2.44 PGx Example
....2.45 HLA Example
...3 HL7 Domain Analysis Use Cases